CAR T-cell therapy, a type of treatment that weaponizes the body’s immune system and was originally developed to treat cancer ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

Estrella Immunopharma ( ($ESLA) ) has shared an announcement. On May 30, 2025, Estrella Immunopharma entered into a securities purchase agreement ...

Estrella Immunopharma (ESLA) announced that it entered into a securities purchase agreement for a private investment in public equity financing ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company ...

In a report released on May 30, analyst Jason McCarthy from Maxim Group maintained a Buy rating on CERo Therapeutics Holdings ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of ...

Researchers sought to determine whether lisocabtagene maraleucel would have efficacy for patients with LBCL in a real-world setting.

Estrella Immunopharma, Inc. (NASDAQ: ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, ...

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company ...